share_log

Aditxt | 8-K: Current report

Aditxt | 8-K: Current report

Aditxt | 8-K:重大事件
美股SEC公告 ·  2024/11/20 05:16

Moomoo AI 已提取核心信息

Aditxt has announced the fourth amendment to its Amended and Restated Merger Agreement with Evofem Biosciences, extending the End Date from November 29, 2024, to January 31, 2025. The merger will result in Evofem becoming a wholly-owned subsidiary of Aditxt.The agreement includes a series of parent equity investments, with Aditxt committing to purchase Evofem's Series F-1 Preferred Stock in multiple tranches. The most recent modification in October 2024 adjusted the Third Parent Equity Investment to $720,000 and increased the Fourth Parent Equity Investment to $2.28 million.The merger agreement, initially signed in December 2023, has undergone several amendments regarding investment timing and amounts. The latest amendment maintains all other terms and conditions of the Amended and Restated Merger Agreement unchanged.
Aditxt has announced the fourth amendment to its Amended and Restated Merger Agreement with Evofem Biosciences, extending the End Date from November 29, 2024, to January 31, 2025. The merger will result in Evofem becoming a wholly-owned subsidiary of Aditxt.The agreement includes a series of parent equity investments, with Aditxt committing to purchase Evofem's Series F-1 Preferred Stock in multiple tranches. The most recent modification in October 2024 adjusted the Third Parent Equity Investment to $720,000 and increased the Fourth Parent Equity Investment to $2.28 million.The merger agreement, initially signed in December 2023, has undergone several amendments regarding investment timing and amounts. The latest amendment maintains all other terms and conditions of the Amended and Restated Merger Agreement unchanged.
Aditxt宣布了与Evofem Biosciences的修订和重新制定的合并协议的第四次修正,将结束日期从2024年11月29日延长至2025年1月31日。合并将导致Evofem成为Aditxt的全资子公司。协议包括一系列母公司股权投资,Aditxt承诺分多批购买Evofem的F-1系列优先股。最近一次的修改是在2024年10月,将第三次母公司股权投资调整为720,000美元,并将第四次母公司股权投资增加至228万。最初在2023年12月签署的合并协议,经过几次关于投资时间和金额的修订。最新的修订保持了修订和重新制定的合并协议的所有其他条款和条件不变。
Aditxt宣布了与Evofem Biosciences的修订和重新制定的合并协议的第四次修正,将结束日期从2024年11月29日延长至2025年1月31日。合并将导致Evofem成为Aditxt的全资子公司。协议包括一系列母公司股权投资,Aditxt承诺分多批购买Evofem的F-1系列优先股。最近一次的修改是在2024年10月,将第三次母公司股权投资调整为720,000美元,并将第四次母公司股权投资增加至228万。最初在2023年12月签署的合并协议,经过几次关于投资时间和金额的修订。最新的修订保持了修订和重新制定的合并协议的所有其他条款和条件不变。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息